Bortezomib (Synonyms: 硼替佐米; PS-341; LDP-341; NSC 681239)

目录号: HY-10227 纯度: 99.99%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Bortezomib (PS-341) 是一种可逆性和选择性的蛋白酶体 (proteasome) 抑制剂，通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (K_i=0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是第一种蛋白酶体抑制剂，具有抗癌活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bortezomib Chemical Structure

CAS No. : 179324-69-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格		是否有货
50 mg		询价
100 mg		询价
250 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Bortezomib:

Bortezomib-d₈ 询价
Bortezomib (Standard) 询价

MCE 顾客使用本产品发表的 154 篇科研文献

Proliferation Assay

: Bortezomib purchased from MCE. Usage Cited in: Mol Cell Biochem. 2023 May 19. [Abstract]; Bortezomib (BTZ; 10 nM; 48 h) significantly enhances the cell death of RPMI-8226.

: Bortezomib purchased from MCE. Usage Cited in: Mol Cell Biochem. 2023 May 19. [Abstract]; Bortezomib (BTZ; 5, 10, 20 nM; 48 h) increases the expression level of γH2AX in RPMI-8226 and U266 cells.

: Bortezomib purchased from MCE. Usage Cited in: Clin Cancer Res. 2019 Jun 15;25(12):3630-3642. [Abstract]; H1975 cells treated with 5 μmol/L MTI-31 alone or in combination with 10 μmol/L CQ or 0.01 μmol/L PS-341.

: Bortezomib purchased from MCE. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]; Different concentrations of two classical proteasome inhibitors Bortezomib and MG132 are added. AGS cells are either untreated or treated with Bortezomib (25 nM) or MG132 (0.1 μM) for 24 h in the absence or presence of baf A1 (100 nM).

: Bortezomib purchased from MCE. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]; AGS cells are pretreated with 25 and 50 nM Bortezomib for 1 h, and then incubated with 500 nM Torin 1 for 24 h. After pretreatment with PPI for 24 h in pH 7.4 or pH 6.5 condition, Rapamycin (1 μM) or Torin 1 (500 nM) is added for another 24 h. The protein level of SQSTM1 is measured by western blot analysis.

: Bortezomib purchased from MCE. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]; Kelly cells are treated with increasing concentrations of Thalidomide and co-treated with 5 μM Bortezomib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.

: Bortezomib purchased from MCE. Usage Cited in: BMC Cancer. 2018 Oct 11;18(1):971. [Abstract]; The reduction of MAGEC2 protein level in TRIM28-knockdown A375 cells can be inhibited by treatment with both MG132 and PS-341, and similar result is also observed in Hs 695 T cells.

: Bortezomib purchased from MCE. Usage Cited in: Eur J Pharmacol. 2017 Nov 15;815:147-155. [Abstract]; Shown are GFPu fluorescent images of the GFPu-HEK293 cells treated with CuSO₄ (Cu, 20 μM), HK (20 μM), HK-Cu (HC, 20 μM), or Velcade (Vel, 100 nM).

Bortezomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
纯度 & 产品资料
参考文献

生物活性

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity^[1]^[2].

IC₅₀ & Target

Ki: 0.6 nM (20S proteasome)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
5TGM1	IC₅₀	6.78 nM Compound: PS-341, Bortezomib	Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
A2780	IC₅₀	28.9 nM Compound: Bortezomib	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 28182990]
A-431	IC₅₀	28.2 nM Compound: Bortezomib	Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
A549	IC₅₀	13.9 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21077681]
A549	IC₅₀	2.14 μM Compound: Bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28634039]
A549	IC₅₀	2.5 nM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 28182990]
A549	IC₅₀	2135.73 nM Compound: PS-341	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27769033]
A549	IC₅₀	255 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19537716]
A549	IC₅₀	6.7 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20158184]
A549	IC₅₀	9.318 μM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29426629]
A549	IC₅₀	92 nM Compound: BTZ	Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
ARH-77	IC₅₀	6.07 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay	[PMID: 26965867]
ARH-77	IC₅₀	9.57 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
BEL-7404 tumor cell line	IC₅₀	25.04 nM Compound: PS-341	Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 27769033]
BGC-823	IC₅₀	2890 nM Compound: Bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19747832]
BGC-823	IC₅₀	880 nM Compound: bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19537716]
BXPC-3	IC₅₀	11.8 nM Compound: Bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19747832]
BXPC-3	IC₅₀	16.2 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
BXPC-3	IC₅₀	19.4 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
Calu-6	IC₅₀	3.9 nM Compound: Bortezomib	Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay	10.1039/C2MD20060K
CCRF-CEM	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
CCRF-CEM	IC₅₀	11 nM Compound: Bortezomib	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
DLD-1	IC₅₀	0.0002 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DLD-1	IC₅₀	0.0009 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
GES1	IC₅₀	12.6 nM Compound: PS-341	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HCT-116	IC₅₀	0.001 μM Compound: Bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28634039]
HCT-116	IC₅₀	0.01 μM Compound: bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 23547757]
HCT-116	IC₅₀	1.4 nM Compound: PS-341	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27769033]
HCT-116	IC₅₀	27 nM Compound: Bortezomib	Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
HEK293	IC₅₀	0.014 μM Compound: PS-341	Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay	[PMID: 21044847]
HEK293	IC₅₀	10 nM Compound: 1, bortezomib	Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay	[PMID: 20875739]
HEK293	IC₅₀	27 nM Compound: 1a, Bortezomib	Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader	[PMID: 21634429]
HEK293	CC₅₀	347 nM Compound: 1a, Bortezomib	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 21634429]
HEK293	IC₅₀	9.7 nM Compound: Bortezomib	Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control	10.1039/C2MD20060K
HEK-293T	IC₅₀	12 nM Compound: BTZ	Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
HeLa	IC₅₀	> 200 nM Compound: Btz	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	0.02 μM Compound: PS-341	Growth inhibition of human HeLa cells after 72 hrs by MTT assay Growth inhibition of human HeLa cells after 72 hrs by MTT assay	[PMID: 19428245]
HeLa	GI₅₀	168.1 μM Compound: BTZ; Product S4	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HeLa	IC₅₀	20 nM Compound: Btz	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	92 nM Compound: bortezomib	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19537716]
HepG2	EC₅₀	0.01 μM Compound: Bortezomib	Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29800827]
HepG2	IC₅₀	1.61 nM Compound: PS-341	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27769033]
HepG2	GI₅₀	100.6 μM Compound: BTZ; Product S4	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HepG2	IC₅₀	25.2 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21077681]
HepG2	IC₅₀	37.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19537716]
HepG2	IC₅₀	7.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20158184]
HET-1A	IC₅₀	25.6 nM Compound: PS-341	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HL-60	ED₅₀	0.0025 μM Compound: Bortezomib	Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay	[PMID: 21973101]
HL-60	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28634039]
HL-60	ED₅₀	2.5 nM Compound: bortezomib	Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins	[PMID: 19422206]
HL-60	IC₅₀	3.2 nM Compound: Bortezomib	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 28182990]
HL-60	IC₅₀	3.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21077681]
HL-60	IC₅₀	5.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19537716]
HL-60	IC₅₀	6.9 nM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19747832]
HL-60	IC₅₀	7.1 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20158184]
HL-60	IC₅₀	7.6 nM Compound: PS-341	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27769033]
HT-29	ED₅₀	> 20 μM Compound: Bortezomib	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	IC₅₀	3.2 nM Compound: Btz	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HUVEC	IC₅₀	11.2 nM Compound: PS-341	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
K562	GI₅₀	0.007 μM Compound: Bortezomib	Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
KB	IC₅₀	59.5 nM Compound: bortezomib	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19537716]
KM3/BTZ	IC₅₀	226 nM Compound: PS-341	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
L02	IC₅₀	55.5 nM Compound: PS-341	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
MCF7	IC₅₀	0.025 μM Compound: Bz	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 28557430]
MCF7	IC₅₀	18.37 μM Compound: Bortezomib	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	IC₅₀	0.003 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.017 μM Compound: Bortezomib	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28634039]
MDA-MB-231	IC₅₀	16.65 nM Compound: PS-341	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27769033]
MDA-MB-231	IC₅₀	3.125 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	IC₅₀	6.5 nM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28182990]
MGC-803	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 28634039]
MGC-803	IC₅₀	5.782 nM Compound: PS-341	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 27769033]
MKN-45	IC₅₀	7.15 nM Compound: PS-341	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 27769033]
MM1.S	IC₅₀	0.0026 μM Compound: Bortezomib	Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
MM1.S	IC₅₀	0.0032 μM Compound: Bortezomib	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
MM1.S	IC₅₀	2.5 nM Compound: BTZ	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
MOLT-4	EC₅₀	21 nM Compound: 8	Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate	[PMID: 22503349]
Multiple myeloma cancer stem cell	IC₅₀	8.4 nM Compound: BTZ	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
NCI-H23	IC₅₀	0.01 μM Compound: Btz	Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H460	IC₅₀	115 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 19537716]
NCI-H460	IC₅₀	780 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 20158184]
NCI-H727	IC₅₀	0.025 μM Compound: Btz	Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H929	IC₅₀	10.85 nM Compound: Bortezomib	Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay	[PMID: 24767818]
PBMC	IC₅₀	< 35 nM Compound: Bortezomib	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
PBMC	IC₅₀	2.7 nM Compound: 1	Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay	[PMID: 31283222]
PC-3	GI₅₀	0.04 μM Compound: Bortezomib	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
PC-3	IC₅₀	7 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
PC-3	IC₅₀	8.3 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
RAW264.7	IC₅₀	0.03 μM Compound: Bortezomib	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay	[PMID: 32738985]
RKO	IC₅₀	20.8 nM Compound: Bortezomib	Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
RPMI-8226	IC₅₀	0.0045 μM Compound: Bortezomib	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
RPMI-8226	IC₅₀	0.0056 μM Compound: Bortezomib	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
RPMI-8226	IC₅₀	0.0064 μM Compound: BTZ	Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay	[PMID: 34445874]
RPMI-8226	IC₅₀	1.43 nM Compound: PS-341	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
RPMI-8226	IC₅₀	11.2 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
RPMI-8226	IC₅₀	3.88 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 26965867]
RPMI-8226	IC₅₀	4.7 nM Compound: BTZ	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
RPMI-8226	IC₅₀	6.7 nM Compound: Bortezomib	Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay	[PMID: 28182990]
RPMI-8226	IC₅₀	7.96 nM Compound: Bortezomib	Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 24767818]
RPMI-8226	IC₅₀	9.5 nM Compound: PS-341, Bortezomib	Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
SK-OV-3	IC₅₀	1.62 nM Compound: PS-341	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27769033]
SK-OV-3	IC₅₀	12.9 nM Compound: Bortezomib	Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay	[PMID: 29767973]
SK-OV-3	IC₅₀	130 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 19537716]
SK-OV-3	IC₅₀	151 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 20158184]
SK-OV-3	IC₅₀	66.8 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 21077681]
SW1990	IC₅₀	79.06 nM Compound: PS-341	Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 27769033]
SW480	IC₅₀	12.3 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 21077681]
SW480	IC₅₀	50 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19537716]
SW480	IC₅₀	6.1 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 20158184]
TOV21G	IC₅₀	16.7 nM Compound: Bortezomib	Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
U-266	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
U-266	IC₅₀	11.63 nM Compound: Bortezomib	Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
U-266	IC₅₀	12.2 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19747832]
U-266	IC₅₀	12.5 nM Compound: PS-341	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
U-266	IC₅₀	2.45 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19537716]
U-266	IC₅₀	5.73 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTS assay Cytotoxicity against human U266 cells after 72 hrs by MTS assay	[PMID: 26965867]
U-266	IC₅₀	8.8 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 20158184]
WM 266-4	IC₅₀	0.035 μM Compound: Bortezomib, Velcade, PS-341	Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay	[PMID: 22206869]

体外研究
(In Vitro)

Bortezomib (PS-341) (100 nM；8 小时) 导致 G2-M 期细胞积累，G1 期细胞数量相应减少^[1]。
Bortezomib (PS-341) (5-100 nM；20 小时) 在套细胞淋巴瘤 (MCL) 细胞系中诱导细胞凋亡^[3]。
Bortezomib (PS-341) (20 nM；1-14 小时) 在两种 MCL 细胞系^[3]中诱导 Noxa 上调。
Bortezomib (PS-341) 的 IC₅₀ 是发现 B16F10 细胞中 26S 蛋白酶体的浓度为 2.46 nM^[4]。
Bortezomib (PS-341) 抑制多种抗凋亡蛋白 (例如，Bcl-XL、Bcl-2、和 STAT-3)^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	PC-3 cells
Concentration:	100 nM
Incubation Time:	8 hours
Result:	Resulted in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1.

Apoptosis Analysis^[3]

Cell Line:	JVM-2, Granta-519, Jeko, REC-1 cells (MCL cell lines)
Concentration:	5-100 nM
Incubation Time:	20 hours
Result:	The median LD50 for these MCL cell lines was 31 nM (range, 18.2-60.1 nM).

Western Blot Analysis^[3]

Cell Line:	wtp53 (Granta-519), mutp53 (Jeko) cells
Concentration:	20 nM
Incubation Time:	1, 2, 4, 6, 14 hours
Result:	Noxa up-regulation was detected between 2 to 4 hours after bortezomib (PS-341).

体内研究
(In Vivo)

Bortezomib (PS-341) (0.3-1 mg/kg；静脉注射；每周一次，持续 4 周) 抑制裸鼠体内的 PC-3 肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice (xenograft tumor model bearing PC-3 cells)^[1]
Dosage:	0.3, 1 mg/kg
Administration:	Intravenous injection; once weekly for 4 weeks
Result:	Resulted in a significant decrease in tumor growth ~60% at dose of 1 mg/kg.

Clinical Trial

分子量

384.24

Formula

C₁₉H₂₅BN₄O₄

CAS 号

179324-69-7

性状

固体

颜色

White to off-white

中文名称

硼替佐米；保特佐米

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

Ethanol 中的溶解度 : 66.67 mg/mL (173.51 mM; 超声助溶 (<60°C))

DMSO 中的溶解度 : 50 mg/mL (130.13 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6025 mL	13.0127 mL	26.0254 mL
5 mM	0.5205 mL	2.6025 mL	5.2051 mL
10 mM	0.2603 mL	1.3013 mL	2.6025 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 4 mg/mL (10.41 mM); 澄清溶液

此方案可获得 ≥ 4 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 40.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 4 mg/mL (10.41 mM); 澄清溶液

此方案可获得 ≥ 4 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 40.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 4 mg/mL (10.41 mM); 澄清溶液

此方案可获得 ≥ 4 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 40.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.51 mM); 澄清溶液
方案五

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.51 mM); 澄清溶液
方案六

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.41 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案七

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.41 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案八

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.41 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案九

请依序添加每种溶剂： 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (1.30 mM); 澄清溶液

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.99%

选择批次：

Data Sheet (646 KB) SDS (557 KB)

COA (288 KB) HNMR (259 KB) RP-HPLC (99 KB) LCMS (96 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [Content Brief]

[2]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24. [Content Brief]

[3]. Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64. [Content Brief]

[4]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. [Content Brief]

[5]. Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12(67):471-80. [Content Brief]

[6]. Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281(2):1107-18. [Content Brief]

Bortezomib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.6025 mL	13.0127 mL	26.0254 mL	65.0635 mL
	5 mM	0.5205 mL	2.6025 mL	5.2051 mL	13.0127 mL
	10 mM	0.2603 mL	1.3013 mL	2.6025 mL	6.5064 mL
	15 mM	0.1735 mL	0.8675 mL	1.7350 mL	4.3376 mL
	20 mM	0.1301 mL	0.6506 mL	1.3013 mL	3.2532 mL
	25 mM	0.1041 mL	0.5205 mL	1.0410 mL	2.6025 mL
	30 mM	0.0868 mL	0.4338 mL	0.8675 mL	2.1688 mL
	40 mM	0.0651 mL	0.3253 mL	0.6506 mL	1.6266 mL
	50 mM	0.0521 mL	0.2603 mL	0.5205 mL	1.3013 mL
	60 mM	0.0434 mL	0.2169 mL	0.4338 mL	1.0844 mL
	80 mM	0.0325 mL	0.1627 mL	0.3253 mL	0.8133 mL
	100 mM	0.0260 mL	0.1301 mL	0.2603 mL	0.6506 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Bortezomib (Synonyms: 硼替佐米; PS-341; LDP-341; NSC 681239)

Customer Review

Other Forms of Bortezomib:

MCE 顾客使用本产品发表的 154 篇科研文献

Bortezomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Bortezomib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Bortezomib (Synonyms: 硼替佐米; PS-341; LDP-341; NSC 681239)

Customer Review

Other Forms of Bortezomib:

Bortezomib 相关抗体

MCE 顾客使用本产品发表的 154 篇科研文献

Bortezomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Bortezomib 相关抗体:

摩尔计算器

稀释计算器

Bortezomib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z